Description
Carboplatin is available in India?
Carboplatin is the salt name for the drug sold under the brand name Carb-Dna. It is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective. It has also been used to treat triple-negative breast cancer. Carboplatin has also been used for adjuvant therapy of stage 1 seminomatous testicular cancer.
Common side effects include low blood cell levels, nausea, and electrolyte problems. Other serious side effects include allergic reactions and mutagenesis. Carboplatin is in the platinum-based antineoplastic family of medications and works by interfering with duplication of DNA.
Will this product be accessible across all regions of India?
The product – Carb-Dna (Carboplatin) Injection will be available across India on request. Carboplatin is available in all the major cities in India – Delhi, Chandigarh, Jodhpur, Patna, Kolkata, Lucknow, Hyderabad, Chennai, Ahmedabad, Bangalore, and Pune. To get or place an order from Aark Pharmaceuticals, a pharma distributor in India, please call us at+91 9999156233, You can also make an inquiry by emailing us at sales@aarkpharma.co.in, sales@aarkpharma.com, WhatsApp: +91 9999156233.
List of available and accessible brand of Carboplatin Injection?
Brand of Carboplatin Injection available and accessible to patients at an affordable price, at the earliest possible time: Biocarb, Carb-Dna, Carbokem, Carbotero, Carbozar, Celcarb, Cytocarb, Innocar.
NEWS / Updates
- Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer.
- Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC.
- Pembrolizumab Plus Carboplatin and Paclitaxel Offers Alternative for Advanced HNSCC.
- Carboplatin increases cure rate, survival of triple negative breast cancer: Study
Written By
Mr. Sandeep Tomar (D. pharma)
Last updated
12 July 2025 | 07:25 AM (IST)
